Please use this identifier to cite or link to this item:
|Title:||Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein - A preliminary study on immunogenicity||Authors:||Yap, I.
|Issue Date:||1992||Citation:||Yap, I., Guan, R., Chan, S.H. (1992). Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein - A preliminary study on immunogenicity. Vaccine 10 (7) : 439-442. ScholarBank@NUS Repository.||Abstract:||A novel recombinant hepatitis B vaccine, trademarked Sci-B-Vac, was evaluated for safety, tolerability and immunogenicity in an open label trial performed in Singapore. The experimental vaccine, derived from Chinese hamster ovary (CHO) cells, consists of hepatitis B surface antigen (HBsAg) particles harbouring all three viral envelope polypeptides, the major S protein and the minor Pre-S2 and Pre-S1, in their glycosylated and non-glycosylated forms. The vaccine was administered intramuscularly at 0, 1 and 6 months. No unexpected adverse effects were observed. A high level anti-HBs response to Sci-B-Vac was indicative of its immunogenicity. Subsequent to the third injection, 100% and 92% of the 10 μg and 5 μg dose recipients, respectively, were seroprotected (anti-HBs titres ≥ 10 mIU ml -1). Moreover, the geometric mean titres (GMT) of the anti-HBs response were very high: 2687 and 1473 mIU ml -1, respectively. An immunogenic advantage of Sci-B-Vac was also suggested by the rapid onset of antibody response: 96% of the 10 μg dose recipients were seroprotected with a GMT of 159 mIU ml -1, prior to the third injection.||Source Title:||Vaccine||URI:||http://scholarbank.nus.edu.sg/handle/10635/131960||ISSN:||0264410X|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.